David Altshuler, EVP, Chief Scientific Officer at VERTEX PHARMACEUTICALS INC / MA (VRTX), sold 5,667 shares at $480.95 ($2.7M) on 2025-02-25, disclosed to the SEC on 2025-02-26.
Scheduled sale ($2.7M) by EVP, Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $483.28 | 3,971 | $1.9M | 70.2% |
| 2 | $480.95 | 848 | $408K | 14.9% |
| 3 | $480.95 | 848 | $408K | 14.9% |
| Total | $482.58 avg | 5,667 | $2.7M | 100% |
| Filing → |
| VRTX | SELL | 2025-03-12 | $1.6M | — | Filing → |
| VRTX | SELL | 2025-03-05 | $1.6M | — | Filing → |
| VRTX | SELL | 2025-02-28 | $611K | — | Filing → |